MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000491402

Медицинская библиотека · Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2018

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.

Finger Robert P, Schmitz-Valckenberg Steffen, Schmid Matthias, Rubin Gary S, Dunbar Hannah, Tufail Adnan, Crabb David P, Binns Alison, Sánchez Clara I, Margaron Philippe, Normand Guillaume, Durbin Mary K, Luhmann Ulrich F O, Zamiri Parisa, Cunha-Vaz José, Asmus Friedrich, Holz Frank G, on behalf of the MACUSTAR consortium

СтатьяОбзорПеревод пока не подготовлен

Аннотация

PURPOSE: Currently, no outcome measures are clinically validated and accepted as clinical endpoints by regulatory agencies for drug development in intermediate age-related macular degeneration (iAMD). The MACUSTAR Consortium, a public-private research group funded by the European Innovative Medicines Initiative intends to close this gap.

PROCEDURES: Development of study protocol and statistical analysis plan including predictive modelling of multimodal endpoints based on a review of the literature and expert consensus.

RESULTS

This observational study consists of a cross-sectional and a longitudinal part. Functional outcome measures assessed under low contrast and low luminance have the potential to detect progression of visual deficit within iAMD and to late AMD. Structural outcome measures will be multimodal and investigate topographical relationships with function. Current patient-reported outcome measures (PROMs) are not acceptable to regulators and may not capture the functional deficit specific to iAMD with needed precision, justifying development of novel PROMs for iAMD. The total sample size will be n = 750, consisting mainly of subjects with iAMD (n = 600).

CONCLUSIONS

As clinical endpoints currently accepted by regulators cannot detect functional loss or patient-relevant impact in iAMD, we will clinically validate novel candidate endpoints for iAMD.

Для цитирования: Finger Robert P, Schmitz-Valckenberg Steffen, Schmid Matthias, Rubin Gary S, Dunbar Hannah, Tufail Adnan, Crabb David P, Binns Alison, Sánchez Clara I, Margaron Philippe, Normand Guillaume, Durbin Mary K, Luhmann Ulrich F O, Zamiri Parisa, Cunha-Vaz José, Asmus Friedrich, Holz Frank G, on behalf of the MACUSTAR consortium. MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2018. DOI: 10.1159/000491402.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.